{"id":"https://openalex.org/W2069080472","doi":"https://doi.org/10.1158/1535-7163.targ-09-b193","title":"Abstract B193: Identification of selective inhibitors of ubiquitin specific proteases","display_name":"Abstract B193: Identification of selective inhibitors of ubiquitin specific proteases","alternate_titles":[],"publication_year":2009,"publication_date":"2009-12-01","ids":{"openalex":"https://openalex.org/W2069080472","doi":"https://doi.org/10.1158/1535-7163.targ-09-b193","mag":"2069080472"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-09-b193","doi":"https://doi.org/10.1158/1535-7163.targ-09-b193","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-09-b193","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2069080472"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103502702","display_name":"Roman Lopez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152921","display_name":"Hybrigenics (France)","ror":"https://ror.org/04nj1pt13","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210152921"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Roman Lopez","raw_affiliation_strings":["Hybrigenics SA, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hybrigenics SA, Paris, France","institution_ids":["https://openalex.org/I4210152921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011981237","display_name":"Vincent Collura","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152921","display_name":"Hybrigenics (France)","ror":"https://ror.org/04nj1pt13","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210152921"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Vincent Collura","raw_affiliation_strings":["Hybrigenics SA, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hybrigenics SA, Paris, France","institution_ids":["https://openalex.org/I4210152921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058640388","display_name":"C\u00e9line Reverdy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152921","display_name":"Hybrigenics (France)","ror":"https://ror.org/04nj1pt13","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210152921"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Ce\u0301line Reverdy","raw_affiliation_strings":["Hybrigenics SA, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hybrigenics SA, Paris, France","institution_ids":["https://openalex.org/I4210152921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024106496","display_name":"C\u00e9cile Planquette","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152921","display_name":"Hybrigenics (France)","ror":"https://ror.org/04nj1pt13","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210152921"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Ce\u0301cile Planquette","raw_affiliation_strings":["Hybrigenics SA, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hybrigenics SA, Paris, France","institution_ids":["https://openalex.org/I4210152921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079266900","display_name":"Susan Conrath","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152921","display_name":"Hybrigenics (France)","ror":"https://ror.org/04nj1pt13","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210152921"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Susan Conrath","raw_affiliation_strings":["Hybrigenics SA, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hybrigenics SA, Paris, France","institution_ids":["https://openalex.org/I4210152921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060444771","display_name":"Philippe Gu\u00e9dat","orcid":"https://orcid.org/0000-0002-7214-1414","observed_orcids":["https://orcid.org/0000-0002-7214-1414"]},"institutions":[{"id":"https://openalex.org/I4210152921","display_name":"Hybrigenics (France)","ror":"https://ror.org/04nj1pt13","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210152921"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Philippe Guedat","raw_affiliation_strings":["Hybrigenics SA, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hybrigenics SA, Paris, France","institution_ids":["https://openalex.org/I4210152921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019706619","display_name":"R\u00e9mi Delansorne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152921","display_name":"Hybrigenics (France)","ror":"https://ror.org/04nj1pt13","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210152921"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Re\u0301mi Delansorne","raw_affiliation_strings":["Hybrigenics SA, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hybrigenics SA, Paris, France","institution_ids":["https://openalex.org/I4210152921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051092031","display_name":"Laurent Daviet","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152921","display_name":"Hybrigenics (France)","ror":"https://ror.org/04nj1pt13","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210152921"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Laurent Daviet","raw_affiliation_strings":["Hybrigenics SA, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hybrigenics SA, Paris, France","institution_ids":["https://openalex.org/I4210152921"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005231854","display_name":"Fr\u00e9d\u00e9ric Colland","orcid":"https://orcid.org/0009-0003-3361-9555","observed_orcids":["https://orcid.org/0009-0003-3361-9555"]},"institutions":[{"id":"https://openalex.org/I4210152921","display_name":"Hybrigenics (France)","ror":"https://ror.org/04nj1pt13","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210152921"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Fre\u0301de\u0301ric Colland","raw_affiliation_strings":["Hybrigenics SA, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hybrigenics SA, Paris, France","institution_ids":["https://openalex.org/I4210152921"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210152921"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"8","issue":"12_Supplement","first_page":"B193","last_page":"B193"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10620","display_name":"Protease and Inhibitor Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ubiquitin-specific-protease","display_name":"ubiquitin-specific protease","score":0.9869999885559082},{"id":"https://openalex.org/keywords/deubiquitination","display_name":"deubiquitination","score":0.9520000219345093},{"id":"https://openalex.org/keywords/ubiquitin-proteasome-system","display_name":"ubiquitin-proteasome system","score":0.9470000267028809},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.703000009059906},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.8370000123977661},{"id":"https://openalex.org/keywords/anticancer-drug-discovery","display_name":"anticancer drug discovery","score":0.718999981880188},{"id":"https://openalex.org/keywords/high-throughput-screening","display_name":"high-throughput screening","score":0.7350000143051147},{"id":"https://openalex.org/keywords/small-molecule-inhibitors","display_name":"small molecule inhibitors","score":0.5989999771118164},{"id":"https://openalex.org/keywords/drug-specificity","display_name":"drug specificity","score":0.33000001311302185}],"concepts":[{"id":"https://openalex.org/C25602115","wikidata":"https://www.wikidata.org/wiki/Q407111","display_name":"Ubiquitin","level":3,"score":0.8146053552627563},{"id":"https://openalex.org/C102658986","wikidata":"https://www.wikidata.org/wiki/Q5266092","display_name":"Deubiquitinating enzyme","level":4,"score":0.7981775403022766},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.7580230236053467},{"id":"https://openalex.org/C10679952","wikidata":"https://www.wikidata.org/wiki/Q5308937","display_name":"Druggability","level":3,"score":0.629259467124939},{"id":"https://openalex.org/C182220744","wikidata":"https://www.wikidata.org/wiki/Q7251226","display_name":"Proteases","level":3,"score":0.6264022588729858},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.4949583411216736},{"id":"https://openalex.org/C51323132","wikidata":"https://www.wikidata.org/wiki/Q626251","display_name":"High-throughput screening","level":2,"score":0.46185457706451416},{"id":"https://openalex.org/C2776714187","wikidata":"https://www.wikidata.org/wiki/Q212410","display_name":"Protease","level":3,"score":0.44610822200775146},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.4404500126838684},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.43827754259109497},{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.43403956294059753},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4286981523036957},{"id":"https://openalex.org/C2908868211","wikidata":"https://www.wikidata.org/wiki/Q4274835","display_name":"Ubiquitin-Protein Ligases","level":5,"score":0.4197292625904083},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.38314756751060486},{"id":"https://openalex.org/C134459356","wikidata":"https://www.wikidata.org/wiki/Q4274835","display_name":"Ubiquitin ligase","level":4,"score":0.29104405641555786},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.11820027232170105}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-09-b193","doi":"https://doi.org/10.1158/1535-7163.targ-09-b193","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-09-b193","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9391000270843506,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2317791466","https://openalex.org/W2121234603","https://openalex.org/W2262088816","https://openalex.org/W2055722788","https://openalex.org/W7171565111","https://openalex.org/W2075394133","https://openalex.org/W4409624621","https://openalex.org/W2914005285","https://openalex.org/W2284280942","https://openalex.org/W4411431741"],"abstract_inverted_index":{"Abstract":[0],"Regulated":[1],"protein":[2],"turnover":[3],"is":[4,85],"primarily":[5],"controlled":[6],"by":[7,90,154],"the":[8,15,33,39,42,58,98,160,173,181,184],"ubiquitin-proteasome":[9],"system.":[10],"The":[11],"therapeutic":[12,26],"efficacy":[13],"of":[14,41,60,97,162,183],"proteasome":[16,34],"inhibitor":[17],"Bortezomib":[18],"establishes":[19],"this":[20],"system":[21],"as":[22,117,137,139,165],"a":[23,74],"valid":[24],"anticancer":[25,50],"field.":[27],"A":[28,93],"promising":[29,118],"alternative":[30],"to":[31,46,79,87,112],"targeting":[32],"itself":[35],"lies":[36],"upstream,":[37],"at":[38],"level":[40],"ubiquitin":[43,130,135],"conjugation/deconjugation":[44],"step":[45],"generate":[47],"more":[48],"specific":[49,61],"agents.":[51],"Ubiquitin-specific":[52],"proteases":[53],"(USP)":[54],"are":[55],"involved":[56],"in":[57,103,159],"deubiquitination":[59],"target":[62,76],"substrates":[63,127,142],"regulating":[64],"their":[65,80],"stability,":[66],"subcellular":[67],"localization":[68],"and/or":[69],"activation":[70],"status.":[71],"USP":[72,126,167],"represent":[73],"druggable":[75],"class":[77],"due":[78],"thiol-protease":[81],"catalytic":[82],"core":[83],"which":[84],"amenable":[86],"pharmacological":[88],"inhibition":[89],"small":[91],"molecules.":[92],"genome-wide":[94],"RNAi":[95],"screen":[96],"catalytically":[99],"active":[100],"human":[101],"USPs":[102],"cancer-relevant":[104],"cellular":[105],"models":[106],"and":[107,115,187],"phenotypic":[108],"assays":[109,123],"allowed":[110],"us":[111],"identify":[113],"USP7/HAUSP":[114],"USP8/UBPY":[116],"cancer":[119],"targets.":[120],"Fluorescence-based":[121],"screening":[122,146],"using":[124],"optimized":[125],"including":[128],"various":[129],"derivatives":[131],"(ubiquitin":[132],"precursor,":[133],"branched":[134],"chains)":[136],"well":[138],"specific,":[140],"physiological":[141],"were":[143],"developed.":[144],"High-throughput":[145],"performed":[147],"on":[148],"our":[149],"chemically":[150],"diverse":[151],"library":[152],"followed":[153],"different":[155],"optimization":[156],"programs":[157],"resulted":[158],"discovery":[161],"several":[163],"series":[164],"novel":[166],"inhibitors.":[168],"Our":[169],"progress":[170],"made":[171],"towards":[172],"specificity":[174],"issue":[175],"will":[176],"be":[177],"presented":[178],"here":[179],"with":[180],"identification":[182],"first":[185],"USP8-":[186],"USP7-specific":[188],"series.":[189],"Citation":[190],"Information:":[191],"Mol":[192],"Cancer":[193],"Ther":[194],"2009;8(12":[195],"Suppl):B193.":[196]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2069080472","counts_by_year":[],"updated_date":"2026-09-21T07:43:02.447757","created_date":"2016-06-24T00:00:00"}
